Views & Analysis Digital health round-up: Hacking medical devices, robot phar... Richard Staines presents a round-up of the week's digital health news
Partner Content Partner Content Insightful Developments and an Exclusive Interview from Roch... Ophthalmic Drugs 2018
News Astellas buys eye gene therapy biotech Quethera for $109m Japanese Astellas Pharma has bought privately-owned biotech Quethera for $109 million, gaining access to its gene therapy focused on developing novel treatments for glaucoma and eye disorde
Partner Content Partner Content Industry news with an exclusive interview by from Aerie Phar... Ophthalmic Drugs
Partner Content Partner Content Gene Therapy bringing new hope to patients and families Ophthalmic Drugs
Partner Content Partner Content Exclusive Interview Released from Santen for Ophthalmic Drug... Exclusive Interview Released from Santen
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
